Results 61 to 70 of about 4,268 (199)

Legal status, sex work engagement and inequities in the HIV pre‐exposure prophylaxis cascade among migrant women in 11 European countries

HIV Medicine, Volume 27, Issue 8, Page 1344-1357, August 2026.
Abstract Background Migrant women account for a substantial proportion of new HIV diagnoses in Europe, yet remain underrepresented in HIV prevention research. Little is known about how legal status and national policy context shape engagement with PrEP among migrant women, particularly those without secure documentation.
Haoyi Wang, Anne Flaherty‐Gupta, Hala Majdoub, Edwin Sesange, Kim Isip, Justine Lubnow, Pedro Barrios Sanchez, Linda Pavanello, Etinosa Erevbenagie‐Johnbull, Lillian Petry, Emma Gooding, Magdalena Ankiersztejn‐Bartczak, Stavroula Triantafyllidou, Ann Piercy, Kai J. Jonas, Denis Onyango, Hanne M. L. Zimmermann, on behalf of the MiHealth HIV Partnership   +17 more
wiley   +1 more source

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial [PDF]

, 2020
Summary Background In phase 1 trials, the HIV-1 integrase strand transfer inhibitor cabotegravir (GSK1265744) was well tolerated, both alone, and in combination with the non-nucleoside reverse transcriptase inhibitor rilpivirine. We assessed cabotegravir

core  

Development and Validation of Stability Indicating RP-HPLC Method for the Simultaneous Estimation of Cabotegravir and Rilpivirine in Bulk and Tablet Dosage Form [PDF]

, 2021
A simple, Accurate, precise method was developed for the simultaneous estimation of the Cabotegravir and Rilpivirine in bulk and Tablet dosage form. Chromatogram was run through Denali C18 (150 x 4.6 mm, 5µ).
Mohammed Rizwan, U
core  

Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With HIV-1 Infection: ~5-Year Results From the LATTE-2 Study

, 2021
Background. In the Long-Acting Antiretroviral Treatment Enabling Trial 2 (LATTE-2) phase 2b study, long-acting (LA) injectable cabotegravir + rilpivirine dosed every 8 weeks (Q8W) or every 4 weeks (Q4W) demonstrated comparable efficacy with daily oral ...
Zhang, Feifan, Van Solingen-Ristea, Rodica, Smith, Kimberly Y., Smith, Graham, Podzamczer Palter, Daniel, Jaeger, Hans, Richmond, Gary J., Mccoig, Cynthia C., Khuong-Josses, Marie-Aude, Bettacchi, Christopher J., Montes, Maria Luisa, Sutton, Kenneth C., Arasteh, Keikawus, Yazdanpanah, Yazdan, Vandermeulen, Kati, Margolis, David A., Spreen, William R., Masiá, Maria Del Mar, Stellbrink, Hans-jürgen, Henry, W. Keith, St. Clair, Marty H.   +20 more
core   +1 more source

Cabotegravir pharmacokinetics in Asians with and without HIV

Int. Journal of Clinical Pharmacology and Therapeutics
Cabotegravir is approved for HIV treatment (with rilpivirine) and prevention. The established cabotegravir population pharmacokinetic (PPK) model included 1.2% Asian participants. We aimed to compare cabotegravir pharmacokinetics between Asian and non-Asian populations and across Asian countries.Cabotegravir concentrations were collected from Asian ...
Han, Kelong, Abulfathi, Ahmed A., Mehta, Rashmi S., Nand, Romina A., Marzinke, Mark A., Landovitz, Raphael J., D’Amico, Ronald D., Rinehart, Alex R., Spreen, William R., Ford, Susan L.   +9 more
openaire   +2 more sources

The effect of long-acting cabotegravir and rilpivirine treatment on drug resistance in South Africa: a modelling study.

Background Long-acting injectable cabotegravir and rilpivirine (LAI cabotegravir and rilpivirine) is recommended as maintenance therapy for people living with HIV who achieved viral suppression on oral antiretroviral therapy (ART). However, its effect on
Loosli, Tom, Johnson, Leigh F, Hauser, Anthony, Egger, Matthias, Günthard, Huldrych F, Kouyos, Roger D, Anderegg, Nanina, Davies, Mary-Ann, Josi, Johannes, Han, Nuri, Lessells, Richard   +10 more
core   +2 more sources

A Bilayer Microarray Patch (MAP) for HIV Pre-Exposure Prophylaxis: The Role of MAP Designs and Formulation Composition in Enhancing Long-Acting Drug Delivery

Pharmaceutics
Microarray patches (MAPs) have shown great potential for efficient and patient-friendly drug delivery through the skin; however, improving their delivery efficiency for long-acting drug release remains a significant challenge.
Lalitkumar K. Vora, Ismaiel A. Tekko, Fabiana Volpe Zanutto, Akmal Sabri, Robert K. M. Choy, Jessica Mistilis, Priscilla Kwarteng, Courtney Jarrahian, Helen O. McCarthy, Ryan F. Donnelly   +9 more
doaj   +1 more source

Comparable real‐world effectiveness between switches to cabotegravir + rilpivirine long‐acting or modern daily oral regimens in the United States: an OPERA cohort study

Journal of the International AIDS Society
Introduction Cabotegravir + rilpivirine long‐acting (CAB+RPV LA) injectable was approved in the United States in 2021 for HIV‐1 treatment in virologically suppressed (viral load [VL]
Ricky K. Hsu, Michael G. Sension, Jennifer S. Fusco, Laurence Brunet, Quateka Cochran, Brooke Levis, Gayathri Sridhar, Vani Vannappagari, Jean Van Wyk, Michael B. Wohlfeiler, Gregory P. Fusco   +10 more
doaj   +1 more source

Using Tenofovir Diphosphate Levels to Evaluate Factors Associated With PrEP Non‐Adherence and Performance of Indirect Adherence Measures in Latin America: A Prospective, Single‐Arm, Open‐Label, Multicentre Implementation Study (ImPrEP)

Journal of the International AIDS Society, Volume 29, Issue S3, July 2026.
ABSTRACT Introduction Tenofovir‐based oral pre‐exposure prophylaxis (PrEP) is pivotal for HIV prevention in Latin America. Monitoring PrEP adherence is crucial for maximizing its impact and identifying individuals who may benefit from additional support.
Thiago S. Torres, Mayara Secco Torres Silva, Brenda Hoagland, Luana Monteiro Spindola Marins, Carolina Coutinho, Emilia M. Jalil, Pedro Leite, Marcelo Cunha, Ronaldo Moreira, Iuri C. Leite, Kelika Konda, Juan Guanira, Marcos Benedetti, Cristina Pimenta, Hamid Vega‐Ramirez, Sandra W. Cardoso, Carlos F. Caceres, Peter L. Anderson, Beatriz Grinsztejn, Valdilea G. Veloso, for ImPrEP Study Group   +20 more
wiley   +1 more source

Cost‐effectiveness of leveraging long‐acting injectable cabotegravir to expand PrEP coverage among MSM in two contrasting North American cities

Journal of the International AIDS Society
Introduction Long‐acting injectable cabotegravir (CAB‐LA) is superior to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for HIV pre‐exposure prophylaxis (PrEP) and could expand PrEP usage.
Jesse A. Heitner, Sarah E. Stansfield, Kate M. Mitchell, Carla M. Doyle, Rachael M. Milwid, Mia Moore, Deborah J. Donnell, Yiqing Xia, Mathieu Maheu‐Giroux, Ruanne V. Barnabas, Marie‐Claude Boily, Dobromir T. Dimitrov   +11 more
doaj   +1 more source